ROSEVILLE, Minn., Jan. 28 /PRNewswire/ -- Parker Hughes Cancer Center oncologists presented two papers with their clinical treatment outcome results for pancreas cancer and colon cancer at the 2005 Gastrointestinal Cancers Symposium co-sponsored by American Society of Clinical Oncology, The Society of Surgical Oncology and American Gastroenterological Association held in Hollywood, Florida, January 27-29, 2005. In advanced metastatic pancreas cancer, the patient-tailored treatments at Parker Hughes Cancer Center guided by fusion imaging, a state-of-the art imaging method which allows doctors to stop ineffective treatments in a timely fashion, were more than 200% better than the national average and thus tripled the survival of patients with otherwise invariably fatal cancer. In metastatic colon cancer, patient- tailored treatments delivered in an outpatient setting resulted in long-term survival of patients.
In addition to these exciting new clinical data, the Center's director, Dr. Fatih Uckun, will give a talk on Saturday, January 29, 2005 regarding a new cancer prevention technology developed at Parker Hughes which prevents polyps from turning into colon cancer. The presentations are posted on Parker Hughes website at http://www.parkerhughes.org/news/index.html .
According to the American Cancer Society there were an estimated 147,000 new cases of colon cancer last year and roughly 57,000 deaths. For pancreas cancer there were an estimated 32,000 new cases and roughly 31,000 deaths.
1. Patient-Tailored Outpatient Chemotherapy Regimens For Inoperable
Advanced Metastatic Pancreas Cancer.
Meeting: 2005 Gastrointestinal Cancers Symposium Abstract No: 89
2. Chemoprevention of Colorectal Cancer By Targeting of Janus Kinase 3
(JAK3). Meeting: 2005 Gastrointestinal Cancers Symposium Abstract No:
3. Patient-Tailored Outpatient Chemotherapy Regimens for Metastatic
Colorectal Cancer Meeting: 2005 Gastrointestinal Cancers Symposium
Abstract No: 176
Parker Hughes Cancer Center
CONTACT: Tom Knisely of Parker Hughes Cancer Center, +1-651-295-2990